Perioperative Pain, Analgesics and Cancer-Related Outcomes: where do we Stand?

References

• Van Den Beuken-Van Everdingen MH , HochstenbachLM , JoostenEA , Tjan-HeijnenVC , JanssenDJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J. Pain Symptom Manage.51(6), 1070–1090 e1079 (2016).
   PubMed Web of Science ®Google Scholar
• Graczyk M , BorkowskaA , KrajnikM. Why patients are afraid of opioid analgesics: a study on opioid perception in patients with chronic pain. Pol. Arch. Intern. Med.128(2), 89–97 (2018).
   PubMedGoogle Scholar
• Greer SM , DaltonJA , CarlsonJ , YoungbloodR. Surgical patients’ fear of addiction to pain medication: the effect of an educational program for clinicians. Clin. J. Pain17(2), 157–164 (2001).
   PubMed Web of Science ®Google Scholar
• Lee M , SilvermanSM , HansenH , PatelVB , ManchikantiL. A comprehensive review of opioid-induced hyperalgesia. Pain Physician14(2), 145–161 (2011).
   PubMed Web of Science ®Google Scholar
• Colvin LA , BullF , HalesTG. Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet393(10180), 1558–1568 (2019).
   PubMed Web of Science ®Google Scholar
• Zheng J , HeJ , WangWet al. The impact of pain and opioids use on survival in cancer patients: results from a population-based cohort study and a meta-analysis. Medicine (Baltimore)99(9), e19306 (2020).
   PubMed Web of Science ®Google Scholar
• Zylla D , KuskowskiMA , GuptaK , GuptaP. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br. J. Anaesth.113(Suppl. 1), I109–I116 (2014).
   PubMedGoogle Scholar
• Page GG . The immune-suppressive effects of pain. Adv. Exp. Med. Biol.521, 117–125 (2003).
   PubMed Web of Science ®Google Scholar
• Dalal S , BrueraE. Pain management for patients with advanced cancer in the opioid epidemic era. Am. Soc. Clin. Oncol. Educ. Book39, 24–35 (2019).
   PubMedGoogle Scholar
• WHO Guidelines Approved by the Guidelines Review Committee. In: WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. World Health Organization, Geneva, Switzlerland (2018).
   Google Scholar
• Calo G , LambertDG. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic. Br. J. Anaesth.121(5), 1105–1114 (2018).
   PubMed Web of Science ®Google Scholar
• Raehal KM , BohnLM. beta-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb. Exp. Pharmacol.219, 427–443 (2014).
   PubMedGoogle Scholar
• Al-Hasani R , BruchasMR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology115(6), 1363–1381 (2011).
   PubMed Web of Science ®Google Scholar
• Waldhoer M , BartlettSE , WhistlerJL. Opioid receptors. Annu. Rev. Biochem.73, 953–990 (2004).
   PubMed Web of Science ®Google Scholar
• Brejchova J , HolanV , SvobodaP. Expression of opioid receptors in cells of the immune system. Int. J. Mol. Sci.22(1), (2020).
   PubMed Web of Science ®Google Scholar
• Ondrovics M , Hoelbl-KovacicA , FuxDA. Opioids: modulators of angiogenesis in wound healing and cancer. Oncotarget8(15), 25783–25796 (2017).
   PubMedGoogle Scholar
• Ramirez MF , GorurA , CataJP. Opioids and cancer prognosis: a summary of the clinical evidence. Neurosci. Lett.746, 135661 (2021).
   PubMed Web of Science ®Google Scholar
• Szczepaniak A , FichnaJ , ZielinskaM. Opioids in cancer development, progression and metastasis: focus on colorectal cancer. Curr. Treat. Options Oncol.21(1), 6 (2020).
   PubMed Web of Science ®Google Scholar
• Renaud AMCaHGaFL . Inhibition by opioids of phagocytosis in peritoneal macrophages. Neuropeptides18(1), 35–40 (1991).
   PubMed Web of Science ®Google Scholar
• Sacerdote P , ManfrediB , MantegazzaP , PaneraiAE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br. J. Pharmacol.121(4), 834–840 (1997).
   PubMed Web of Science ®Google Scholar
• Wigmore T , Farquhar-SmithP. Opioids and cancer: friend or foe?Curr Opin Support Palliat Care.10(2), 109–118 (2016).
   PubMed Web of Science ®Google Scholar
• Plein LM , RittnerHL. Opioids and the immune system – friend or foe. Br. J. Pharmacol.175(14), 2717–2725 (2018).
   PubMed Web of Science ®Google Scholar
• Franchi S , MoschettiG , AmodeoG , SacerdoteP. Do all opioid drugs share the same immunomodulatory properties? a review from animal and human studies. Front. Immunol.10, 2914 (2019).
   PubMed Web of Science ®Google Scholar
• Hutchinson MR , ZhangY , ShridharMet al. Evidence that opioids may have Toll-like receptor 4 and MD-2 effects. Brain Behav. Immun.24(1), 83–95 (2010).
   PubMed Web of Science ®Google Scholar
• Mahbuba W , LambertDG. Opioids and neovascularization; pro or anti?Br. J. Anaesth.115(6), 821–824 (2015).
   PubMed Web of Science ®Google Scholar
• Carli M , DonniniS , PellegriniC , CoppiE , BocciG. Opioid receptors beyond pain control: the role in cancer pathology and the debated importance of their pharmacological modulation. Pharmacol. Res.159, 104938 (2020).
   PubMed Web of Science ®Google Scholar
• Cheng S , GuoM , LiuZet al. Morphine promotes the angiogenesis of postoperative recurrent tumors and metastasis of dormant breast cancer cells. Pharmacology104(5–6), 276–286 (2019).
   PubMed Web of Science ®Google Scholar
• Polakiewicz RD , SchieferlSM , DornerLF , KansraV , CombMJ. A mitogen-activated protein kinase pathway is required for mu-opioid receptor desensitization. J. Biol. Chem.273(20), 12402–12406 (1998).
   PubMed Web of Science ®Google Scholar
• Liu W , ChenY , XuWet al. Fentanyl stimulates tumor angiogenesis via activating multiple pro-angiogenic signaling pathways. Biochem. Biophys. Res. Commun.532(2), 225–230 (2020).
   PubMed Web of Science ®Google Scholar
• Karaman H , TufekA , KaramanE , TokgozO. Opioids inhibit angiogenesis in a chorioallantoic membrane model. Pain Physician20(2S), SE11–SE21 (2017).
   PubMedGoogle Scholar
• Khabbazi S , NassarZD , GoumonY , ParatMO. Morphine decreases the pro-angiogenic interaction between breast cancer cells and macrophages in vitro. Sci. Rep.6, 31572 (2016).
   PubMed Web of Science ®Google Scholar
• Shi Y , LuoJ , TianJ , ZouQ , WangX. The kappa opioid receptor may be a potential tumor suppressor by regulating angiogenesis in breast cancer. Med. Hypotheses150, 110568 (2021).
   PubMed Web of Science ®Google Scholar
• Mathew B , LennonFE , SieglerJet al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth. Analg.112(3), 558–567 (2011).
   PubMed Web of Science ®Google Scholar
• Gorur A , PatinoM , TakahashiHet al. Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. Life Sci.278, 119541 (2021).
   PubMed Web of Science ®Google Scholar
• Li Y , LiG , TaoTet al. The mu-opioid receptor (MOR) promotes tumor initiation in hepatocellular carcinoma. Cancer Lett.453, 1–9 (2019).
   PubMed Web of Science ®Google Scholar
• Tuerxun H , CuiJ. The dual effect of morphine on tumor development. Clin. Transl. Oncol.21(6), 695–701 (2019).
   PubMed Web of Science ®Google Scholar
• Ramirez MF , GorurA , CataJP. The role of opioids in cancer progression. Int. Anesthesiol. Clin.58(2), 57–63 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang J , YaoN , TianS. Morphine stimulates migration and growth and alleviates the effects of chemo drugs via AMPK-dependent induction of epithelial-mesenchymal transition in esophageal carcinoma cells. Biol. Pharm. Bull.43(5), 774–781 (2020).
   PubMed Web of Science ®Google Scholar
• Niu DG , PengF , ZhangWet al. Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer. Oncotarget6(6), 3963–3976 (2015).
   PubMedGoogle Scholar
• Cao LH , LiHT , LinWQet al. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci. Rep.6, 18706 (2016).
   PubMed Web of Science ®Google Scholar
• Naderi J , SamaniF , AmooheidariA , JavanmardS , VahabzadehG , VaseghiG. Evaluation of effects of morphine and ionizing radiation in cancer cell lines. J. Cancer Res. Ther.15(8), 144–152 (2019).
   Google Scholar
• Botticelli A , CirilloA , PomatiGet al. The role of opioids in cancer response to immunotherapy. J. Transl. Med.19(1), 119 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang HW , WangF , ZhouYQ , XuSP , YuSY , ZhangZG. Morphine suppresses liver cancer cell tumor properties in vitro and in vivo. Front. Oncol.11, 666446 (2021).
   PubMed Web of Science ®Google Scholar
• Zagon IS . Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int. J. Oncol.33(2), 317–323 (2008).
   PubMed Web of Science ®Google Scholar
• Donahue RN , MclaughlinPJ , ZagonIS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol. Oncol.122(2), 382–388 (2011).
   PubMed Web of Science ®Google Scholar
• Zagon IS , PorterfieldNK , MclaughlinPJ. Opioid growth factor – opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer. Exp. Biol. Med. (Maywood).238(6), 589–599 (2013).
   PubMed Web of Science ®Google Scholar
• Lec PM , LenisAT , GollaVet al. The role of opioids and their receptors in urological malignancy: a review. J. Urol.204(6), 1150–1159 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang H , SunM , ZhouDet al. Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br. J. Anaesth.125(5), 722–729 (2020).
   PubMed Web of Science ®Google Scholar
• Singleton PA , MirzapoiazovaT , HasinaR , SalgiaR , MossJ. Increased mu-opioid receptor expression in metastatic lung cancer. Br. J. Anaesth.113(Suppl. 1), i103–108 (2014).
   PubMedGoogle Scholar
• Zhang H , QuM , GorurAet al. Association of Mu-opioid receptor(MOR) expression and opioids requirement with survival in patients with stage I–III pancreatic ductal adenocarcinoma. Front. Oncol.11, 686877 (2021).
   PubMed Web of Science ®Google Scholar
• Diaz-Cambronero O , MazzinariG , GinerFet al. Mu opioid receptor 1 (MOR-1) expression in colorectal cancer and oncological long-term outcomes: a five-year retrospective longitudinal cohort study. Cancers (Basel)12(1), (2020).
   PubMed Web of Science ®Google Scholar
• Steele GL , DudekAZ , GilmoreGEet al. Impact of pain, opioids, and the mu-opioid receptor on progression and survival in patients with newly diagnosed stage IV pancreatic cancer. Am. J. Clin. Oncol.43(8), 591–597 (2020).
   PubMed Web of Science ®Google Scholar
• Cata JP , KeertyV , KeertyDet al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med.3(4), 900–908 (2014).
   PubMed Web of Science ®Google Scholar
• Wuethrich PY , ThalmannGN , StuderUE , BurkhardFC. Epidural analgesia during open radical prostatectomy does not improve long-term cancer-related outcome: a retrospective study in patients with advanced prostate cancer. PLoS ONE8(8), e72873 (2013).
   PubMed Web of Science ®Google Scholar
• Wu HL , TaiYH , ChangWKet al. Does postoperative morphine consumption for acute surgical pain impact oncologic outcomes after colorectal cancer resection?: a retrospective cohort study. Medicine (Baltimore)98(18), e15442 (2019).
   PubMed Web of Science ®Google Scholar
• Cata JP , ZafereoM , VillarrealJet al. Intraoperative opioids use for laryngeal squamous cell carcinoma surgery and recurrence: a retrospective study. J. Clin. Anesth.27(8), 672–679 (2015).
   PubMed Web of Science ®Google Scholar
• Du KN , FengL , NewhouseAet al. Effects of intraoperative opioid use on recurrence-free and overall survival in patients with esophageal adenocarcinoma and squamous cell carcinoma. Anesth. Analg.127(1), 210–216 (2018).
   PubMed Web of Science ®Google Scholar
• Montagna G , GuptaHV , HannumMet al. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br. J. Anaesth.126(2), 367–376 (2021).
   PubMed Web of Science ®Google Scholar
• Sessler DI , PeiL , HuangYet al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet394(10211), 1807–1815 (2019).
   PubMed Web of Science ®Google Scholar
• Rangel FP , AulerJOCJr , CarmonaMJCet al. Opioids and premature biochemical recurrence of prostate cancer: a randomised prospective clinical trial. Br. J. Anaesth.126(5), 931–939 (2021).
   PubMed Web of Science ®Google Scholar
• Du Y-T , LiY-W , ZhaoB-Jet al. Long-term survival after combined epidural–general anesthesia or general anesthesia alone: follow-up of a randomized trial. Anesthesiology135(2), 233–245 (2021).
   PubMed Web of Science ®Google Scholar
• Kurdi MS , TheerthKA , DevaRS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth. Essays Res.8(3), 283–290 (2014).
   PubMedGoogle Scholar
• Clark JD . Ketamine for chronic pain: old drug new trick?Anesthesiology133(1), 13–15 (2020).
   PubMed Web of Science ®Google Scholar
• Bell RF , EcclestonC , KalsoEA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst. Rev.6, CD003351 (2017).
   PubMed Web of Science ®Google Scholar
• Zorumski CF , IzumiY , MennerickS. Ketamine: NMDA receptors and beyond. J. Neurosci.36(44), 11158–11164 (2016).
   PubMed Web of Science ®Google Scholar
• Abdollahpour A , SaffariehE , ZoroufchiBH. A review on the recent application of ketamine in management of anesthesia, pain, and health care. J. Family Med. Prim. Care9(3), 1317–1324 (2020).
   PubMedGoogle Scholar
• Duan W , HuJ , LiuY. Ketamine inhibits colorectal cancer cells malignant potential via blockage of NMDA receptor. Exp. Mol. Pathol.107, 171–178 (2019).
   PubMed Web of Science ®Google Scholar
• Malsy M , GebhardtK , GruberM , WieseC , GrafB , BundschererA. Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesthesiol.15, 111 (2015).
   PubMed Web of Science ®Google Scholar
• Zhou X , ZhangP , LuoWet al. Ketamine induces apoptosis in lung adenocarcinoma cells by regulating the expression of CD69. Cancer Med.7(3), 788–795 (2018).
   PubMed Web of Science ®Google Scholar
• Connolly JG , TanKS , MastrogiacomoBet al. Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. Br. J. Anaesth.127(1), 75–84 (2021).
   PubMed Web of Science ®Google Scholar
• Cho JS , KimNY , ShimJ-K , JunJH , LeeS , KwakY-L. The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. Can. J. Anesth.68(5), 683–692 (2021).
   PubMed Web of Science ®Google Scholar
• Masic D , LiangE , LongC , SterkEJ , BarbasB , RechMA. Intravenous lidocaine for acute pain: a systematic review. Pharmacotherapy38(12), 1250–1259 (2018).
   PubMed Web of Science ®Google Scholar
• Dunn LK , DurieuxME. Perioperative use of intravenous lidocaine. Anesthesiology126(4), 729–737 (2017).
   PubMed Web of Science ®Google Scholar
• Lee JT , SandersonCR , XuanW , AgarM. Lidocaine for cancer pain in adults: a systematic review and meta-analysis. J. Palliat. Med.22(3), 326–334 (2019).
   PubMed Web of Science ®Google Scholar
• Cata JP , RamirezMF , VelasquezJFet al. Lidocaine stimulates the function of natural killer cells in different experimental settings. Anticancer Res.37(9), 4727–4732 (2017).
   PubMed Web of Science ®Google Scholar
• Wang H-L , YanH-D , LiuY-Yet al. Intraoperative intravenous lidocaine exerts a protective effect on cell-mediated immunity in patients undergoing radical hysterectomy. Mol. Med. Report.12(5), 7039–7044 (2015).
   PubMed Web of Science ®Google Scholar
• Jeon YT , NaH , RyuH , ChungY. Modulation of dendritic cell activation and subsequent Th1 cell polarization by lidocaine. PLoS ONE10(10), e0139845 (2015).
   PubMed Web of Science ®Google Scholar
• Galos EV , TatTF , PopaRet al. Neutrophil extracellular trapping and angiogenesis biomarkers after intravenous or inhalation anaesthesia with or without intravenous lidocaine for breast cancer surgery: a prospective, randomised trial. Br. J. Anaesth.125(5), 712–721 (2020).
   PubMed Web of Science ®Google Scholar
• Carrithers MD , ChatterjeeG , CarrithersLMet al. Regulation of podosome formation in macrophages by a splice variant of the sodium channel SCN8A. J. Biol. Chem.284(12), 8114–8126 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang L , HuR , ChengYet al. Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A. Cell Prolif.50(5), (2017).
   Web of Science ®Google Scholar
• Sui H , LouA , LiZ , YangJ. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer19(1), 233 (2019).
   PubMedGoogle Scholar
• Gao R , CaoT , ChenH , CaiJ , LeiM , WangZ. Nav1.5-E3 antibody inhibits cancer progression. Transl Cancer Res.8(1), 44–50 (2019).
   PubMed Web of Science ®Google Scholar
• Xing W , ChenDT , PanJHet al. Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiology126(5), 868–881 (2017).
   PubMed Web of Science ®Google Scholar
• Leng T , LinS , XiongZ , LinJ. Lidocaine suppresses glioma cell proliferation by inhibiting TRPM7 channels. Int. J. Physiol. Pathophysiol. Pharmacol.9(2), 8–15 (2017).
   PubMedGoogle Scholar
• Wen J , LiX , DingY , ZhengS , XiaoY. Lidocaine inhibits glioma cell proliferation, migration and invasion by modulating the circEZH2/miR-181b-5p pathway. Neuroreport32(1), 52–60 (2021).
   PubMed Web of Science ®Google Scholar
• D’agostino G , SaporitoA , CecchinatoVet al. Lidocaine inhibits cytoskeletal remodelling and human breast cancer cell migration. Br. J. Anaesth.121(4), 962–968 (2018).
   PubMed Web of Science ®Google Scholar
• Gao J , HuH , WangX. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling. Cancer Chemother. Pharmacol.83(6), 1007–1015 (2019).
   PubMed Web of Science ®Google Scholar
• Du J , ZhangL , MaH , WangY , WangP. Lidocaine suppresses cell proliferation and aerobic glycolysis by regulating circHOMER1/miR-138-5p/HEY1 axis in colorectal cancer. Cancer Manag. Res.12, 5009–5022 (2020).
   PubMed Web of Science ®Google Scholar
• Yang X , ZhaoL , LiMet al. Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer. Sci. Rep.8(1), 598 (2018).
   PubMedGoogle Scholar
• Zhang X , PangW , LiuH , WangJ. Lidocine potentiates the cytotoxicity of 5-fluorouracil to choriocarcinoma cells by downregulating ABC transport proteins expression. J. Cell. Biochem.120(10), 16533–16542 (2019).
   PubMed Web of Science ®Google Scholar
• Zhu J , HanS. Lidocaine inhibits cervical cancer cell proliferation and induces cell apoptosis by modulating the lncRNA-MEG3/miR-421/BTG1 pathway. Am. J. Transl. Res.11(9), 5404–5416 (2019).
   PubMed Web of Science ®Google Scholar
• Ramirez MF , TranP , CataJP. The effect of clinically therapeutic plasma concentrations of lidocaine on natural killer cell cytotoxicity. Reg. Anesth. Pain Med.40(1), 43–48 (2015).
   PubMed Web of Science ®Google Scholar
• Galoş EV , TatT-F , PopaRet al. Neutrophil extracellular trapping and angiogenesis biomarkers after intravenous or inhalation anaesthesia with or without intravenous lidocaine for breast cancer surgery: a prospective, randomised trial. Br. J. Anaesth.125(5), 712–721 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang H , YangL , ZhuXet al. Association between intraoperative intravenous lidocaine infusion and survival in patients undergoing pancreatectomy for pancreatic cancer: a retrospective study. Br. J. Anaesth.125(2), 141–148 (2020).
   PubMed Web of Science ®Google Scholar
• Mattia C , ColuzziF. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anesthesiol.71(7–8), 461–470 (2005).
   PubMedGoogle Scholar
• Yoshimura N , SanoH , OkamotoMet al. Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg. Today33(11), 805–811 (2003).
   PubMed Web of Science ®Google Scholar
• Huh J , LiepinsA , ZielonkaJ , AndrekopoulosC , KalyanaramanB , SorokinA. Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity. Cancer Res.66(7), 3726–3736 (2006).
   PubMed Web of Science ®Google Scholar
• Desai SJ , PrickrilB , RasoolyA. Mechanisms of phytonutrient modulation of cyclooxygenase-2 (COX-2) and inflammation related to cancer. Nutr. Cancer70(3), 350–375 (2018).
   PubMed Web of Science ®Google Scholar
• Kulkarni S , RaderJS , ZhangFet al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res.7(2), 429–434 (2001).
   PubMed Web of Science ®Google Scholar
• Soslow RA , DannenbergAJ , RushDet al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer89(12), 2637–2645 (2000).
   PubMed Web of Science ®Google Scholar
• Molina MA , Sitja-ArnauM , LemoineMG , FrazierML , SinicropeFA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res.59(17), 4356–4362 (1999).
   PubMed Web of Science ®Google Scholar
• Kazberuk A , ZarebaI , PalkaJ , SurazynskiA. A novel plausible mechanism of NSAIDs-induced apoptosis in cancer cells: the implication of proline oxidase and peroxisome proliferator-activated receptor. Pharmacol. Rep.72(5), 1152–1160 (2020).
   PubMed Web of Science ®Google Scholar
• Wu Y , ZhouBP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle8(20), 3267–3273 (2009).
   PubMed Web of Science ®Google Scholar
• Liu B , QuL , YanS. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int.15, 106 (2015).
   PubMed Web of Science ®Google Scholar
• Huang XZ , GaoP , SunJXet al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control26(4), 589–600 (2015).
   PubMed Web of Science ®Google Scholar
• Johnson CC , JankowskiM , RolnickS , YoodMU , AlfordSH. Influence of NSAID use among colorectal cancer survivors on cancer outcomes. Am. J. Clin. Oncol.40(4), 370–374 (2017).
   PubMed Web of Science ®Google Scholar
• Iovoli AJ , HermannGM , MaSJet al. Association of nonsteroidal anti-inflammatory drug use with survival in patients with squamous cell carcinoma of the head and neck treated with chemoradiation therapy. JAMA Netw Open.3(6), e207199 (2020).
   PubMed Web of Science ®Google Scholar
• Choi JE , VillarrealJ , LasalaJet al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study. Cancer Med.4(6), 825–833 (2015).
   PubMed Web of Science ®Google Scholar
• Forget P , TombalB , ScholtesJLet al. Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer? Eur. J. Anaesthesiol. 28(12), 830–835 (2011).
   PubMed Web of Science ®Google Scholar
• Zhao X , XuZ , LiH. NSAIDs use and reduced metastasis in cancer patients: results from a meta-analysis. Sci. Rep.7(1), 1875 (2017).
   PubMed Web of Science ®Google Scholar
• Magee DJ , JhanjiS , PoulogiannisG , Farquhar-SmithP , BrownMRD. Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence. Br. J. Anaesth.123(2), e412–e423 (2019).
   PubMed Web of Science ®Google Scholar
• Cata JP , GuerraCE , ChangGJ , GottumukkalaV , JoshiGP. Non-steroidal anti-inflammatory drugs in the oncological surgical population: beneficial or harmful? A systematic review of the literature. Br. J. Anaesth.119(4), 750–764 (2017).
   PubMed Web of Science ®Google Scholar
• Forget P , BentinC , MachielsJP , BerliereM , CouliePG , DeKock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br. J. Anaesth.113(Suppl. 1), i82–87 (2014).
   PubMedGoogle Scholar
• Forget P , MachielsJ-P , CouliePet al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann. Surg. Oncol.20, 650–660 (2013).
   Web of Science ®Google Scholar
• Grahn O , LundinM , LydrupML , AngeneteE , RutegårdM. Postoperative non-steroidal anti-inflammatory drug use and oncological outcomes of rectal cancer. BJS Open5(1), (2021).
   PubMed Web of Science ®Google Scholar
• Forget P , VandenhendeJ , BerliereMet al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth. Analg.110(6), 1630–1635 (2010).
   PubMed Web of Science ®Google Scholar
• Yang EV , SoodAK , ChenMet al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res.66(21), 10357–10364 (2006).
   PubMed Web of Science ®Google Scholar
• Lee BM , RodriguezA , MenaGet al. Platelet-to-lymphocyte ratio and use of NSAIDs during the perioperative period as prognostic indicators in patients with NSCLC undergoing surgery. Cancer Control23(3), 284–294 (2016).
   PubMed Web of Science ®Google Scholar
• De Castro Araujo BL , DeOliveira JL , RezendeJFN , NogueraWS , DeMelo AC , ThulerLCS. Impact of non-steroidal anti-inflammatory drugs on recurrence and survival after melanoma surgery: a cohort study. Cancer Invest.38(7), 415–423 (2020).
   PubMed Web of Science ®Google Scholar
• Wang RD , ZhuJY , ZhuY , GeYS , XuGL , JiaWD. Perioperative analgesia with parecoxib sodium improves postoperative pain and immune function in patients undergoing hepatectomy for hepatocellular carcinoma. J. Eval. Clin. Pract.26(3), 992–1000 (2019).
   PubMed Web of Science ®Google Scholar
• Forget P , BoucheGet al. Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. PLoS ONE14(12), e0225748 (2019).
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA , ShiQ , FuchsCSet al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer. JAMA325(13), (2021).
   PubMed Web of Science ®Google Scholar
• Patel R , DickensonAH. Mechanisms of the gabapentinoids and alpha 2 delta-1 calcium channel subunit in neuropathic pain. Pharmacol. Res. Perspect.4(2), e00205 (2016).
   PubMed Web of Science ®Google Scholar
• Dethloff L , BarrB , BesterveltLet al. Gabapentin-induced mitogenic activity in rat pancreatic acinar cells. Toxicol. Sci.55(1), 52–59 (2000).
   PubMed Web of Science ®Google Scholar
• Bugan I , KaragozZ , AltunS , DjamgozMB. Gabapentin, an analgesic used against cancer-associated neuropathic pain: effects on prostate cancer progression in an in vivo rat model. Basic Clin. Pharmacol. Toxicol.118(3), 200–207 (2016).
   PubMed Web of Science ®Google Scholar
• Ding Y , RobbinsJ , FraserSP , GrimesJA , DjamgozMB. Comparative studies of intracellular Ca2+ in strongly and weakly metastatic rat prostate cancer cell lines. Int. J. Biochem. Cell Biol.38(3), 366–375 (2006).
   PubMed Web of Science ®Google Scholar
• Irizarry MC , WebbDJ , BoudiafNet al. Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. Pharmacoepidemiol. Drug Saf.21(2), 214–225 (2012).
   PubMed Web of Science ®Google Scholar
• Zhao Y , HeJ , YuN , JiaC , WangS. Mechanisms of dexmedetomidine in neuropathic pain. Front. Neurosci.14, 330 (2020).
   PubMed Web of Science ®Google Scholar
• Brown EN , PavoneKJ , NaranjoM. Multimodal general anesthesia: theory and practice. Anesth. Analg.127(5), 1246–1258 (2018).
   PubMed Web of Science ®Google Scholar
• Lavon H , MatznerP , BenbenishtyAet al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br. J. Anaesth.120(1), 188–196 (2018).
   PubMed Web of Science ®Google Scholar
• Wang C , DatooT , ZhaoHet al. Midazolam and dexmedetomidine affect neuroglioma and lung carcinoma cell biology in vitro and in vivo. Anesthesiology129(5), 1000–1014 (2018).
   PubMed Web of Science ®Google Scholar
• Castillo LF , RiveroEM , GoffinV , LuthyIA. Alpha2-adrenoceptor agonists trigger prolactin signaling in breast cancer cells. Cell. Signal.34, 76–85 (2017).
   PubMed Web of Science ®Google Scholar
• Chen P , LuoX , DaiGet al. Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. Exp. Mol. Med.52(7), 1062–1074 (2020).
   PubMed Web of Science ®Google Scholar
• Tian H , HouL , XiongY , ChengQ. Dexmedetomidine upregulates microRNA-185 to suppress ovarian cancer growth via inhibiting the SOX9/Wnt/beta-catenin signaling pathway. Cell Cycle20(8), 765–780 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang P , HeH , BaiY , LiuW , HuangL. Dexmedetomidine suppresses the progression of esophageal cancer via miR-143-3p/epidermal growth factor receptor pathway substrate 8 axis. Anticancer Drugs31(7), 693–701 (2020).
   PubMed Web of Science ®Google Scholar
• Dong W , ChenMH , YangYHet al. The effect of dexmedetomidine on expressions of inflammatory factors in patients with radical resection of gastric cancer. Eur. Rev. Med. Pharmacol. Sci.21(15), 3510–3515 (2017).
   PubMed Web of Science ®Google Scholar
• Wang Y , XuX , LiuH , JiF. Effects of dexmedetomidine on patients undergoing radical gastrectomy. J. Surg. Res.194(1), 147–153 (2015).
   PubMed Web of Science ®Google Scholar
• Liu Y , SunJ , WuTet al. Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: a prospective randomized controlled trial. Cancer Med.8(18), 7603–7612 (2019).
   PubMed Web of Science ®Google Scholar
• Cata JP , SinghV , LeeBMet al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J. Anaesthesiol. Clin. Pharmacol.33(3), 317–323 (2017).
   PubMedGoogle Scholar